Cai M. Roberts

Midwestern University — United States

Medicine · Health Sciences

13h-index770citations52works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(15), MicroRNA in disease regulation(9), Epigenetics and DNA Methylation(9), RNA modifications and cancer(8), RNA Interference and Gene Delivery(7)

Publications52 total

Naltrexone Has Variable and Schedule-Dependent Effects on Oral Squamous Cell Carcinoma Cells
International Journal of Molecular Sciences·2025Open Access
A Tale of Two Cell Lines: Characterization of differential efficacy of small molecule drugs cediranib and NU-7441 on primary vs. metastatic colorectal cancer
2025
Naltrexone has variable and schedule-dependent effects on oral squamous cell carcinoma cells
2025Open Access
Abstract 610: Manzamine and mitragynine: investigation of beta carboline compounds from marine sponges and kratom leaves as ovarian cancer therapeutics
Cancer Research·2025
Putative Biomarkers for Prognosis, Epithelial-to-Mesenchymal Transition, and Drug Response in Cell Lines Representing Oral Squamous Cell Carcinoma Progression
Genes·2025· 4 citedOpen Access
Characterization of Biomarkers Indicative of Tumor Progression, Epithelial to Mesenchymal Transition, and Response to Cytotoxic Drugs in Oral Squamous Cell Carcinoma
Preprints.org·2024Open Access
Shake It Up Baby Now: The Changing Focus on TWIST1 and Epithelial to Mesenchymal Transition in Cancer and Other Diseases
International Journal of Molecular Sciences·2023· 7 citedOpen Access
Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib
Cancers·2023· 6 citedOpen Access
Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild Type Ovarian Cancer Cells to Olaparib
Preprints.org·2023· 5 citedOpen Access
Supplementary Figure 1 from p53–Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT
2023Open Access
Supplementary Figure 2 from p53–Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT
2023Open Access
Supplementary Figure 6 from p53–Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT
2023Open Access
Supplementary Figure 6 from p53–Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT
2023Open Access
Supplementary Table 1 to 4 from p53–Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT
2023Open Access
Data from p53–Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT
2023Open Access
Supplementary Figure 1 from p53–Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT
2023Open Access
Supplementary Figure 4 from p53–Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT
2023Open Access
Data from p53–Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT
2023Open Access
Supplementary Figure 3 from p53–Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT
2023Open Access
Supplementary Figure 4 from p53–Pirh2 Complex Promotes Twist1 Degradation and Inhibits EMT
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Carlotta A. Glackin(33), Gil Mor(25), Roslyn Tedja(23), Ayesha B. Alvero(22), Yang Yang‐Hartwich(20), Jamie Goodner-Bingham(17), Marta Gurea(17), Natália J. Sumi(17), Carlos Cárdenas(16), James Finlay(11), Thanh H. Dellinger(9), Gina Lowe(7), Mary Pitruzzello(6), Joana Loeza(5), Ernest Han(5), Carlos Aguirre(5), Wei Wen(4), Gang Yin(4), Elena Ratner(4), Sophia Allaf Shahin(3)